Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- JCR: EPO Biosimilar Props Up Business
June 13, 2011
- Patent Office to Resume Discussions on Patent Extension for DDS Formulations
June 13, 2011
- Korosho Approves Kowa's Menstrual Pain Relieving Agents as Class 1 OTC Drug
June 13, 2011
- Lilly Transfers Evista to Takeda in 7 Asian Markets
June 13, 2011
- Promotion Office Discussing Establishment of “Drug Discovery Support Institute”
June 13, 2011
- Prof. Kadowaki to Collect Evidence under Intensified Therapy Using Incretin-related Drugs
June 13, 2011
- Kyowa Kirin, Ferring to Copromote Desmopressin ODT for Enuresis
June 13, 2011
- Korosho to Make Unapproved Drugs under Development Available for Use
June 13, 2011
- Nippon Shinyaku to Market 3 PH Treatments Mid-decade
June 13, 2011
- Rights to PD Treatment KW-6002 in North America Returned to Kyowa Kirin
June 13, 2011
- Ono, DSP to Codevelop CTS as Additional Indication for Limaprost
June 13, 2011
- Bendamustine to Be Marketed by Eisai in South Korea: SymBio
June 13, 2011
- BMS, Roche to Collaborate in PI/II Trials of Combination Treatment for Melanoma
June 13, 2011
- Astellas Looking for Partner for Global Development of Darexaban
June 6, 2011
- ASKA's Emergency Pill Priced at ¥10,000/Dose
June 6, 2011
- Teijin Pharma to Collect More Evidence on Efficacy of Feburic for Hyperuricemia
June 6, 2011
- JPA Opposes Drug Price Revision without Revision of Medical, Nursing Fees
June 6, 2011
- Santen Regains Top Spot in Domestic Glaucoma Market
June 6, 2011
- Sitagliptin Approved for Combination Therapy with αGI: MSD, Ono
June 6, 2011
- Seikagaku Preparing to Launch Gel-One in US Despite Patent Dispute
June 6, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…